Skip to main content

Table 2 A comparison of the incidence of haematological and hepatic adverse effects between patients prescribed 2 g and 4 g daily of ceftriaxone over a 7 month period

From: Haematological and hepatic adverse effects of ceftriaxone in ambulatory care: a dual-centre retrospective observational analysis of standard vs high dose

 

2 g (n = 47)

4 g (n = 39)

OR

OR 95% CI

p value

Analysis of neutrophil count

 Neutropenic

8 (17%)

6 (15.4%)

0.89

0.26–2.63

 > 0.999

Analysis of platelet count

 Thrombocytopenia

0 (0%)

3 (7.7%)

N/A

N/A

0.089

Analysis of ALT level

 ALT > 3 × upper limit

5 (10.6%)

2 (5.1%)

0.45

0.87–2.36

0.448

Analysis of ALP level

 ALP > 3 × upper limit

1 (2.1%)

0

N/A

N/A

 > 0.999

Treatment cessation due to adverse effects

 Treatment cessation due to adverse effects

2 (4.3%)

3 (7.7%)

1.86

0.36–10.92

0.655

  1. A description of the odds ratio calculated to determine probability of the adverse effect occurring and the statistical significance of the odds ratio (p < 0.05 for statistical significance)